{
    "organizations": [],
    "uuid": "4ec89d5f2b25975e4de9241b0c05144055937055",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-canbridge-l/brief-puma-biotechnology-and-canbridge-life-sciences-enter-into-exclusive-licensing-agreement-idUSFWN1PR19S",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN GREATER CHINA\n* PUMA BIOTECHNOLOGY - CANBRIDGE WILL DEVELOP AND COMMERCIALIZE NERLYNX (NERATINIB) IN MAINLAND CHINA, TAIWAN, HONG KONG, AND MACAU\n* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT PAYMENT OF $30 MILLION\n* PUMA BIOTECHNOLOGY - CO TO GET UPFRONT PAYMENT OF $30 MILLION AND POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $40 MILLION\n* PUMA BIOTECHNOLOGY - TO GET SIGNIFICANT DOUBLE-DIGIT ROYALTIES ON NERLYNX SALES IN GREATER CHINA AND POTENTIAL MILESTONE PAYMENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T05:36:00.000+02:00",
    "crawled": "2018-02-02T13:10:25.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "canbridge",
        "life",
        "science",
        "enter",
        "exclusive",
        "licensing",
        "agreement",
        "commercialize",
        "neratinib",
        "greater",
        "china",
        "puma",
        "biotechnology",
        "canbridge",
        "develop",
        "commercialize",
        "nerlynx",
        "neratinib",
        "mainland",
        "china",
        "taiwan",
        "hong",
        "kong",
        "macau",
        "puma",
        "biotechnology",
        "say",
        "receive",
        "upfront",
        "payment",
        "million",
        "puma",
        "biotechnology",
        "co",
        "get",
        "upfront",
        "payment",
        "million",
        "potential",
        "milestone",
        "payment",
        "totaling",
        "million",
        "puma",
        "biotechnology",
        "get",
        "significant",
        "royalty",
        "nerlynx",
        "sale",
        "greater",
        "china",
        "potential",
        "milestone",
        "payment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}